董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Harwin | 男 | Director | 35 | 25.27万美元 | 未持股 | 2021-04-30 |
| Jonathan Violin | 男 | President, Chief Executive Officer and Director | 45 | 未披露 | 未持股 | 2021-04-30 |
| Tomas Kiselak | 男 | Director | 35 | 29.39万美元 | 9.26 | 2021-04-30 |
| Arlene M. Morris | 女 | Director | 69 | 27.14万美元 | 9.58 | 2021-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason A. Leverone | 男 | Chief Financial Officer, Treasurer, and Secretary | 47 | 48.30万美元 | 未持股 | 2021-04-30 |
| Jonathan Violin | 男 | President, Chief Executive Officer and Director | 45 | 未披露 | 未持股 | 2021-04-30 |
| Barrett Katz | 男 | Chief Medical Officer | 71 | 216.08万美元 | 未持股 | 2021-04-30 |
董事简历
中英对照 | 中文 | 英文- Peter Harwin
-
Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。
Peter Harwin has served as a member of Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University. - Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。
- Peter Harwin has served as a member of Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University.
- Jonathan Violin
-
Jonathan Violin自2025年8月起担任Korsana首席执行官兼总裁，自2025年9月起担任Korsana董事会成员。在加入Korsana之前，Violin博士曾于2024年10月至2025年3月期间担任Crescent Biopharma，Inc.（纳斯达克：CBIO）的临时首席执行官兼总裁。Violin博士于2021年1月至2023年2月期间担任生物制药公司Viridian Therapeutics, Inc.（纳斯达克：VRDN）的总裁、首席执行官和董事会成员，此前于2020年10月至2021年1月期间担任Viridian总裁兼首席运营官。Dr. Violin是Viridian前身的联合创始人，并在2020年4月至被收购期间领导其运营。Violin博士自2024年10月起担任Crescent Biopharma，Inc.（纳斯达克：CBIO）的董事会成员，自2019年7月起担任其共同创立的生物技术公司Dianthus Therapeutics，Inc.（TERM1：DNTH）的董事会成员。Violin博士还于2018年与他人共同创立了生物技术公司Quellis Biosciences，Inc.（被Astria Therapeutics, Inc.（纳斯达克：ATXS）收购，前身为缓解制药公司），并于2021年1月在Astria Therapeutics董事会任职，直至2026年1月被Biocryst医药收购。在此之前，Dr. Violin与他人共同创立并帮助领导了一家生物技术公司Trevena Inc.（纳斯达克：TRVN），在2008年至2018年11月期间担任过多个职务，最近担任过高级副总裁、科学事务和投资者关系官。Violin博士在加州大学圣地亚哥分校生物医学科学项目药理学系获得博士学位，在杜克大学Fuqua商学院获得卫生部门管理专业的工商管理硕士学位，并在杜克大学获得化学药理学学士学位。
Jonathan Violin has served as Korsana's Chief Executive Officer and President since August 2025 and as a member of the Korsana Board since September 2025. Prior to joining Korsana, Dr. Violin served as the interim Chief Executive Officer and President of Crescent Biopharma, Inc. (Nasdaq: CBIO) from October 2024 to March 2025. Dr. Violin served as President, Chief Executive Officer and member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company, from January 2021 to February 2023, and he previously served as President and Chief Operating Officer of Viridian from October 2020 until January 2021. Dr. Violin was the Co Founder of Viridian's predecessor and led its operations from April 2020 to its acquisition. Dr. Violin has served as a member of the board of directors of Crescent Biopharma, Inc. (Nasdaq: CBIO) since October 2024 and Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a biotechnology company he co founded, since July 2019. Dr. Violin also co founded Quellis Biosciences, Inc., a biotechnology company (acquired by Astria Therapeutics, Inc. (Nasdaq: ATXS), formerly Catabasis Pharmaceuticals, Inc.), in 2018 and served on the Astria Therapeutics board of directors from January 2021 until its acquisition by BioCryst Pharmaceuticals in January 2026. Prior to that, Dr. Violin co founded and helped lead Trevena Inc. (Nasdaq: TRVN), a biotechnology company, in various roles from 2008 until November 2018, including most recently as Senior Vice President, Scientific Affairs and Investor Relations Officer. Dr. Violin received a Ph.D. from the Department of Pharmacology in the Biomedical Sciences Program at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business at Duke University, and a B.S. in Chemical Pharmacology from Duke University. - Jonathan Violin自2025年8月起担任Korsana首席执行官兼总裁，自2025年9月起担任Korsana董事会成员。在加入Korsana之前，Violin博士曾于2024年10月至2025年3月期间担任Crescent Biopharma，Inc.（纳斯达克：CBIO）的临时首席执行官兼总裁。Violin博士于2021年1月至2023年2月期间担任生物制药公司Viridian Therapeutics, Inc.（纳斯达克：VRDN）的总裁、首席执行官和董事会成员，此前于2020年10月至2021年1月期间担任Viridian总裁兼首席运营官。Dr. Violin是Viridian前身的联合创始人，并在2020年4月至被收购期间领导其运营。Violin博士自2024年10月起担任Crescent Biopharma，Inc.（纳斯达克：CBIO）的董事会成员，自2019年7月起担任其共同创立的生物技术公司Dianthus Therapeutics，Inc.（TERM1：DNTH）的董事会成员。Violin博士还于2018年与他人共同创立了生物技术公司Quellis Biosciences，Inc.（被Astria Therapeutics, Inc.（纳斯达克：ATXS）收购，前身为缓解制药公司），并于2021年1月在Astria Therapeutics董事会任职，直至2026年1月被Biocryst医药收购。在此之前，Dr. Violin与他人共同创立并帮助领导了一家生物技术公司Trevena Inc.（纳斯达克：TRVN），在2008年至2018年11月期间担任过多个职务，最近担任过高级副总裁、科学事务和投资者关系官。Violin博士在加州大学圣地亚哥分校生物医学科学项目药理学系获得博士学位，在杜克大学Fuqua商学院获得卫生部门管理专业的工商管理硕士学位，并在杜克大学获得化学药理学学士学位。
- Jonathan Violin has served as Korsana's Chief Executive Officer and President since August 2025 and as a member of the Korsana Board since September 2025. Prior to joining Korsana, Dr. Violin served as the interim Chief Executive Officer and President of Crescent Biopharma, Inc. (Nasdaq: CBIO) from October 2024 to March 2025. Dr. Violin served as President, Chief Executive Officer and member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company, from January 2021 to February 2023, and he previously served as President and Chief Operating Officer of Viridian from October 2020 until January 2021. Dr. Violin was the Co Founder of Viridian's predecessor and led its operations from April 2020 to its acquisition. Dr. Violin has served as a member of the board of directors of Crescent Biopharma, Inc. (Nasdaq: CBIO) since October 2024 and Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a biotechnology company he co founded, since July 2019. Dr. Violin also co founded Quellis Biosciences, Inc., a biotechnology company (acquired by Astria Therapeutics, Inc. (Nasdaq: ATXS), formerly Catabasis Pharmaceuticals, Inc.), in 2018 and served on the Astria Therapeutics board of directors from January 2021 until its acquisition by BioCryst Pharmaceuticals in January 2026. Prior to that, Dr. Violin co founded and helped lead Trevena Inc. (Nasdaq: TRVN), a biotechnology company, in various roles from 2008 until November 2018, including most recently as Senior Vice President, Scientific Affairs and Investor Relations Officer. Dr. Violin received a Ph.D. from the Department of Pharmacology in the Biomedical Sciences Program at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business at Duke University, and a B.S. in Chemical Pharmacology from Duke University.
- Tomas Kiselak
-
Tomas Kiselak自2024年11月起担任Korsana董事会成员。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是他于2016年4月共同创立的一家医疗投资公司。在加入Fairmount之前，他是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2020年10月起担任Viridian的董事会成员，并自2023年6月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO）的董事，自2023年6月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE），自2020年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。
Tomas Kiselak has served as a member of the Korsana board of directors since November 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian's board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr. Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College. - Tomas Kiselak自2024年11月起担任Korsana董事会成员。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是他于2016年4月共同创立的一家医疗投资公司。在加入Fairmount之前，他是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2020年10月起担任Viridian的董事会成员，并自2023年6月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO）的董事，自2023年6月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE），自2020年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。
- Tomas Kiselak has served as a member of the Korsana board of directors since November 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian's board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr. Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College.
- Arlene M. Morris
-
Arlene M. Morris，她一直担任Palatin的董事（2015年6月以来）。自2015年5月起，她担任Willow Advisors, LLC（生物技术公司的业务发展、商业发展和企业战略咨询公司）的首席执行官。2012年4月至2015年5月，她担任Syndax Pharmaceuticals, Inc.（一家私营生物制药公司，专注于治疗耐药癌症的表观遗传疗法的开发和商业化）的总裁兼首席执行官，并于2011年5月至2015年5月担任董事会成员。2003年至2011年1月，她担任Affymax, Inc.（上市的生物技术公司）的总裁、首席执行官和董事会成员。她还曾在Clearview Projects, Inc.（企业咨询公司）、Coulter Pharmaceutical, Inc.（公开上市的制药公司）、Scios Inc.（公开上市的生物制药公司）和Johnson & Johnson（公开上市的医疗保健公司）担任各种管理和执行职位。她目前是Viridian Therapeutics, Inc.（公开交易的治疗抗体公司）和Cogent Biosciences, Inc.（公开交易的肿瘤生物制药公司）的董事会成员，并曾担任Viveve Medical, Inc.（公开交易的女性医疗保健医疗设备公司）的董事，直到2023年2月，Neovacs SA（公开交易的法国公司），Biodel Inc.（公开交易的专业制药公司）。从2015年到2016年与Albireo Limited和Dimension Therapeutics, Inc.（上市的基因治疗公司）合并，直到2017年被Ultragenyx Pharmaceutical Inc.收购。她持有Carlow College的生物和化学学士学位。
Arlene M. Morris has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment resistant cancers and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a publicly traded therapeutic antibody company, Cogent Biosciences, Inc. (Nasdaq: COGT), a publicly traded oncology biopharmaceutical company, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company. She was previously a director of TC Biopharm (Holdings) PLC (Nasdaq: TCBP), a United Kingdom biopharmaceutical company, until October 2025, Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College. - Arlene M. Morris，她一直担任Palatin的董事（2015年6月以来）。自2015年5月起，她担任Willow Advisors, LLC（生物技术公司的业务发展、商业发展和企业战略咨询公司）的首席执行官。2012年4月至2015年5月，她担任Syndax Pharmaceuticals, Inc.（一家私营生物制药公司，专注于治疗耐药癌症的表观遗传疗法的开发和商业化）的总裁兼首席执行官，并于2011年5月至2015年5月担任董事会成员。2003年至2011年1月，她担任Affymax, Inc.（上市的生物技术公司）的总裁、首席执行官和董事会成员。她还曾在Clearview Projects, Inc.（企业咨询公司）、Coulter Pharmaceutical, Inc.（公开上市的制药公司）、Scios Inc.（公开上市的生物制药公司）和Johnson & Johnson（公开上市的医疗保健公司）担任各种管理和执行职位。她目前是Viridian Therapeutics, Inc.（公开交易的治疗抗体公司）和Cogent Biosciences, Inc.（公开交易的肿瘤生物制药公司）的董事会成员，并曾担任Viveve Medical, Inc.（公开交易的女性医疗保健医疗设备公司）的董事，直到2023年2月，Neovacs SA（公开交易的法国公司），Biodel Inc.（公开交易的专业制药公司）。从2015年到2016年与Albireo Limited和Dimension Therapeutics, Inc.（上市的基因治疗公司）合并，直到2017年被Ultragenyx Pharmaceutical Inc.收购。她持有Carlow College的生物和化学学士学位。
- Arlene M. Morris has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment resistant cancers and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a publicly traded therapeutic antibody company, Cogent Biosciences, Inc. (Nasdaq: COGT), a publicly traded oncology biopharmaceutical company, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company. She was previously a director of TC Biopharm (Holdings) PLC (Nasdaq: TCBP), a United Kingdom biopharmaceutical company, until October 2025, Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College.
高管简历
中英对照 | 中文 | 英文- Jason A. Leverone
JasonA.Leverone自2017年2月起担任我们的首席财务官，秘书和财务主管。在加入我们之前，Leverone先生于2008年11月加入Private Miragen，担任其财务和运营高级总监，并于2010年3月被任命为财务Vice President。Leverone先生于2012年2月被任命为二等兵Miragen&；8217；s首席财务官。加入Private Miragen之前，Leverone从2005年11月到2008年11月担任Replidyne，Inc.（一家上市生物技术公司）金融高级主管和财务总监。加入Replidyne之前，Leverone从2002年9月到2005年10月担任CreekPath System，Inc.（一家国际软件开发公司）企业总监。他的职业生涯始于任职Ernst and Young LLP的会计师事务所，在那里他最后担任高级会计师，随后任职Arthur Andersen LLP，在那里他最后担任审计经理。Leverone先生是一名注册会计师，在布莱恩特大学（Bryant University）获得工商管理学士学位。
Jason A. Leverone has served as our Chief Financial Officer since February 2012. Prior to serving as our Chief Financial Officer, he served as Senior Director of Finance and Operations for then-private corporation Miragen Therapeutics, Inc. “Private Miragen” from November 2008 and was appointed Vice President Finance in March 2010 where he oversaw the company's financial, accounting, and operations functions. Prior to joining Private Miragen, Mr. Leverone was Senior Director of Finance and Controller for Replidyne, Inc., a publicly-traded biotechnology company, from November 2005 to November 2008. Prior to joining Replidyne, Mr. Leverone was the Corporate Controller for CreekPath System, Inc., an international software development company, from September 2002 to October 2005. He commenced his professional career with the accounting firm of Ernst and Young LLP, where he last served as a senior accountant, and then Arthur Andersen LLP, where he last served as an audit manager. Mr. Leverone is a Certified Public Accountant and earned a B.S. in Business Administration from Bryant University.- JasonA.Leverone自2017年2月起担任我们的首席财务官，秘书和财务主管。在加入我们之前，Leverone先生于2008年11月加入Private Miragen，担任其财务和运营高级总监，并于2010年3月被任命为财务Vice President。Leverone先生于2012年2月被任命为二等兵Miragen&；8217；s首席财务官。加入Private Miragen之前，Leverone从2005年11月到2008年11月担任Replidyne，Inc.（一家上市生物技术公司）金融高级主管和财务总监。加入Replidyne之前，Leverone从2002年9月到2005年10月担任CreekPath System，Inc.（一家国际软件开发公司）企业总监。他的职业生涯始于任职Ernst and Young LLP的会计师事务所，在那里他最后担任高级会计师，随后任职Arthur Andersen LLP，在那里他最后担任审计经理。Leverone先生是一名注册会计师，在布莱恩特大学（Bryant University）获得工商管理学士学位。
- Jason A. Leverone has served as our Chief Financial Officer since February 2012. Prior to serving as our Chief Financial Officer, he served as Senior Director of Finance and Operations for then-private corporation Miragen Therapeutics, Inc. “Private Miragen” from November 2008 and was appointed Vice President Finance in March 2010 where he oversaw the company's financial, accounting, and operations functions. Prior to joining Private Miragen, Mr. Leverone was Senior Director of Finance and Controller for Replidyne, Inc., a publicly-traded biotechnology company, from November 2005 to November 2008. Prior to joining Replidyne, Mr. Leverone was the Corporate Controller for CreekPath System, Inc., an international software development company, from September 2002 to October 2005. He commenced his professional career with the accounting firm of Ernst and Young LLP, where he last served as a senior accountant, and then Arthur Andersen LLP, where he last served as an audit manager. Mr. Leverone is a Certified Public Accountant and earned a B.S. in Business Administration from Bryant University.
- Jonathan Violin
Jonathan Violin自2025年8月起担任Korsana首席执行官兼总裁，自2025年9月起担任Korsana董事会成员。在加入Korsana之前，Violin博士曾于2024年10月至2025年3月期间担任Crescent Biopharma，Inc.（纳斯达克：CBIO）的临时首席执行官兼总裁。Violin博士于2021年1月至2023年2月期间担任生物制药公司Viridian Therapeutics, Inc.（纳斯达克：VRDN）的总裁、首席执行官和董事会成员，此前于2020年10月至2021年1月期间担任Viridian总裁兼首席运营官。Dr. Violin是Viridian前身的联合创始人，并在2020年4月至被收购期间领导其运营。Violin博士自2024年10月起担任Crescent Biopharma，Inc.（纳斯达克：CBIO）的董事会成员，自2019年7月起担任其共同创立的生物技术公司Dianthus Therapeutics，Inc.（TERM1：DNTH）的董事会成员。Violin博士还于2018年与他人共同创立了生物技术公司Quellis Biosciences，Inc.（被Astria Therapeutics, Inc.（纳斯达克：ATXS）收购，前身为缓解制药公司），并于2021年1月在Astria Therapeutics董事会任职，直至2026年1月被Biocryst医药收购。在此之前，Dr. Violin与他人共同创立并帮助领导了一家生物技术公司Trevena Inc.（纳斯达克：TRVN），在2008年至2018年11月期间担任过多个职务，最近担任过高级副总裁、科学事务和投资者关系官。Violin博士在加州大学圣地亚哥分校生物医学科学项目药理学系获得博士学位，在杜克大学Fuqua商学院获得卫生部门管理专业的工商管理硕士学位，并在杜克大学获得化学药理学学士学位。
Jonathan Violin has served as Korsana's Chief Executive Officer and President since August 2025 and as a member of the Korsana Board since September 2025. Prior to joining Korsana, Dr. Violin served as the interim Chief Executive Officer and President of Crescent Biopharma, Inc. (Nasdaq: CBIO) from October 2024 to March 2025. Dr. Violin served as President, Chief Executive Officer and member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company, from January 2021 to February 2023, and he previously served as President and Chief Operating Officer of Viridian from October 2020 until January 2021. Dr. Violin was the Co Founder of Viridian's predecessor and led its operations from April 2020 to its acquisition. Dr. Violin has served as a member of the board of directors of Crescent Biopharma, Inc. (Nasdaq: CBIO) since October 2024 and Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a biotechnology company he co founded, since July 2019. Dr. Violin also co founded Quellis Biosciences, Inc., a biotechnology company (acquired by Astria Therapeutics, Inc. (Nasdaq: ATXS), formerly Catabasis Pharmaceuticals, Inc.), in 2018 and served on the Astria Therapeutics board of directors from January 2021 until its acquisition by BioCryst Pharmaceuticals in January 2026. Prior to that, Dr. Violin co founded and helped lead Trevena Inc. (Nasdaq: TRVN), a biotechnology company, in various roles from 2008 until November 2018, including most recently as Senior Vice President, Scientific Affairs and Investor Relations Officer. Dr. Violin received a Ph.D. from the Department of Pharmacology in the Biomedical Sciences Program at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business at Duke University, and a B.S. in Chemical Pharmacology from Duke University.- Jonathan Violin自2025年8月起担任Korsana首席执行官兼总裁，自2025年9月起担任Korsana董事会成员。在加入Korsana之前，Violin博士曾于2024年10月至2025年3月期间担任Crescent Biopharma，Inc.（纳斯达克：CBIO）的临时首席执行官兼总裁。Violin博士于2021年1月至2023年2月期间担任生物制药公司Viridian Therapeutics, Inc.（纳斯达克：VRDN）的总裁、首席执行官和董事会成员，此前于2020年10月至2021年1月期间担任Viridian总裁兼首席运营官。Dr. Violin是Viridian前身的联合创始人，并在2020年4月至被收购期间领导其运营。Violin博士自2024年10月起担任Crescent Biopharma，Inc.（纳斯达克：CBIO）的董事会成员，自2019年7月起担任其共同创立的生物技术公司Dianthus Therapeutics，Inc.（TERM1：DNTH）的董事会成员。Violin博士还于2018年与他人共同创立了生物技术公司Quellis Biosciences，Inc.（被Astria Therapeutics, Inc.（纳斯达克：ATXS）收购，前身为缓解制药公司），并于2021年1月在Astria Therapeutics董事会任职，直至2026年1月被Biocryst医药收购。在此之前，Dr. Violin与他人共同创立并帮助领导了一家生物技术公司Trevena Inc.（纳斯达克：TRVN），在2008年至2018年11月期间担任过多个职务，最近担任过高级副总裁、科学事务和投资者关系官。Violin博士在加州大学圣地亚哥分校生物医学科学项目药理学系获得博士学位，在杜克大学Fuqua商学院获得卫生部门管理专业的工商管理硕士学位，并在杜克大学获得化学药理学学士学位。
- Jonathan Violin has served as Korsana's Chief Executive Officer and President since August 2025 and as a member of the Korsana Board since September 2025. Prior to joining Korsana, Dr. Violin served as the interim Chief Executive Officer and President of Crescent Biopharma, Inc. (Nasdaq: CBIO) from October 2024 to March 2025. Dr. Violin served as President, Chief Executive Officer and member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company, from January 2021 to February 2023, and he previously served as President and Chief Operating Officer of Viridian from October 2020 until January 2021. Dr. Violin was the Co Founder of Viridian's predecessor and led its operations from April 2020 to its acquisition. Dr. Violin has served as a member of the board of directors of Crescent Biopharma, Inc. (Nasdaq: CBIO) since October 2024 and Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a biotechnology company he co founded, since July 2019. Dr. Violin also co founded Quellis Biosciences, Inc., a biotechnology company (acquired by Astria Therapeutics, Inc. (Nasdaq: ATXS), formerly Catabasis Pharmaceuticals, Inc.), in 2018 and served on the Astria Therapeutics board of directors from January 2021 until its acquisition by BioCryst Pharmaceuticals in January 2026. Prior to that, Dr. Violin co founded and helped lead Trevena Inc. (Nasdaq: TRVN), a biotechnology company, in various roles from 2008 until November 2018, including most recently as Senior Vice President, Scientific Affairs and Investor Relations Officer. Dr. Violin received a Ph.D. from the Department of Pharmacology in the Biomedical Sciences Program at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business at Duke University, and a B.S. in Chemical Pharmacology from Duke University.
- Barrett Katz
Barrett Katz自2021年1月起担任我们的首席医疗官。在成为首席医疗官之前，Katz博士于2019年6月至2020年10月担任上市生物制药公司BridgeBio Pharma, Inc.的Retinagenix和Fortify子公司的总裁兼首席医疗官。此前，Katz博士于2017年11月至2019年10月担任基因治疗公司GenSight Biologics的首席医疗官，负责其眼科基因治疗计划的监督。在此之前，从2010年到2017年，他曾担任Montefiore Medical Center和纽约Albert Einstein College of Medicine的眼科主任，眼科，神经病学和神经外科教授。在加入Montefiore和Albert Einstein College of Medicine之前，Katz博士从事生物技术行业和药物开发领域已有数年。他曾担任多瑙河制药公司的首席执行官，Fovea制药公司的首席医疗官，以及Eyetech公司的医疗事务和战略副总裁。在进入工业界之前，他在学术界拥有杰出的职业生涯，并担任由乔治华盛顿大学和美国食品和药物管理局共同赞助的眼科药物开发联合奖学金的联合主任。Katz博士在凯斯-西储大学医学院获得医学学位。他在达拉斯的帕克兰医院完成了内科实习，在国立卫生研究院担任神经病毒学的研究人员助理，并分别在哈佛大学和塔夫茨-新英格兰医学中心完成了神经病学和眼科的住院治疗。他在哈佛大学和加州大学旧金山分校获得了奖学金。Katz博士在罗切斯特大学西蒙商学院获得了工商管理硕士学位，并曾在加利福尼亚大学圣地亚哥和旧金山分校，罗切斯特大学，康奈尔大学和纽约大学任职。
Barrett Katz has served as our Chief Medical Officer since January 2021. Prior to becoming Chief Medical Officer, Dr. Katz was the President and Chief Medical Officer of the Retinagenix and Fortify subsidiaries of BridgeBio Pharma, Inc., a publicly-traded biopharmaceutical company, from June 2019 through October 2020. Previously, Dr. Katz served as the Chief Medical Officer of GenSight Biologics, a gene therapy company, from November 2017 to October 2019 with oversight for their gene therapy programs in Ophthalmology. Prior to that, he served as the DeJur Chair of Ophthalmology and Professor of Ophthalmology, Neurology and Neurosurgery at Montefiore Medical Center and the Albert Einstein College of Medicine in New York from 2010 until 2017. Before joining Montefiore and the Albert Einstein College of Medicine, Dr. Katz had been engaged in the biotech industry and drug development space for several years. He served as Chief Executive Officer of Danube Pharmaceuticals, Chief Medical Officer of Fovea Pharmaceuticals and Vice President of Medical Affairs and Strategy at Eyetech. Before moving to industry, he had a distinguished career in academia and served as co-director of a joint fellowship in ophthalmologic drug development co-sponsored by The George Washington University and the U.S. Food and Drug Administration. Dr. Katz received his medical degree from Case-Western Reserve University School of Medicine. He completed an internship in Internal Medicine at Parkland Hospital in Dallas, served as a research staff associate in Neuro-Virology at the National Institutes of Health, and completed residencies at Harvard University and Tufts-New England Medical Center in both Neurology and Ophthalmology, respectively. He completed fellowships at Harvard and the University of California, San Francisco UCSF. Dr. Katz obtained an M.B.A. from the University of Rochester's Simon School of Business and has served on the faculties of the University of California at San Diego and San Francisco, the University of Rochester, Cornell University and New York University.- Barrett Katz自2021年1月起担任我们的首席医疗官。在成为首席医疗官之前，Katz博士于2019年6月至2020年10月担任上市生物制药公司BridgeBio Pharma, Inc.的Retinagenix和Fortify子公司的总裁兼首席医疗官。此前，Katz博士于2017年11月至2019年10月担任基因治疗公司GenSight Biologics的首席医疗官，负责其眼科基因治疗计划的监督。在此之前，从2010年到2017年，他曾担任Montefiore Medical Center和纽约Albert Einstein College of Medicine的眼科主任，眼科，神经病学和神经外科教授。在加入Montefiore和Albert Einstein College of Medicine之前，Katz博士从事生物技术行业和药物开发领域已有数年。他曾担任多瑙河制药公司的首席执行官，Fovea制药公司的首席医疗官，以及Eyetech公司的医疗事务和战略副总裁。在进入工业界之前，他在学术界拥有杰出的职业生涯，并担任由乔治华盛顿大学和美国食品和药物管理局共同赞助的眼科药物开发联合奖学金的联合主任。Katz博士在凯斯-西储大学医学院获得医学学位。他在达拉斯的帕克兰医院完成了内科实习，在国立卫生研究院担任神经病毒学的研究人员助理，并分别在哈佛大学和塔夫茨-新英格兰医学中心完成了神经病学和眼科的住院治疗。他在哈佛大学和加州大学旧金山分校获得了奖学金。Katz博士在罗切斯特大学西蒙商学院获得了工商管理硕士学位，并曾在加利福尼亚大学圣地亚哥和旧金山分校，罗切斯特大学，康奈尔大学和纽约大学任职。
- Barrett Katz has served as our Chief Medical Officer since January 2021. Prior to becoming Chief Medical Officer, Dr. Katz was the President and Chief Medical Officer of the Retinagenix and Fortify subsidiaries of BridgeBio Pharma, Inc., a publicly-traded biopharmaceutical company, from June 2019 through October 2020. Previously, Dr. Katz served as the Chief Medical Officer of GenSight Biologics, a gene therapy company, from November 2017 to October 2019 with oversight for their gene therapy programs in Ophthalmology. Prior to that, he served as the DeJur Chair of Ophthalmology and Professor of Ophthalmology, Neurology and Neurosurgery at Montefiore Medical Center and the Albert Einstein College of Medicine in New York from 2010 until 2017. Before joining Montefiore and the Albert Einstein College of Medicine, Dr. Katz had been engaged in the biotech industry and drug development space for several years. He served as Chief Executive Officer of Danube Pharmaceuticals, Chief Medical Officer of Fovea Pharmaceuticals and Vice President of Medical Affairs and Strategy at Eyetech. Before moving to industry, he had a distinguished career in academia and served as co-director of a joint fellowship in ophthalmologic drug development co-sponsored by The George Washington University and the U.S. Food and Drug Administration. Dr. Katz received his medical degree from Case-Western Reserve University School of Medicine. He completed an internship in Internal Medicine at Parkland Hospital in Dallas, served as a research staff associate in Neuro-Virology at the National Institutes of Health, and completed residencies at Harvard University and Tufts-New England Medical Center in both Neurology and Ophthalmology, respectively. He completed fellowships at Harvard and the University of California, San Francisco UCSF. Dr. Katz obtained an M.B.A. from the University of Rochester's Simon School of Business and has served on the faculties of the University of California at San Diego and San Francisco, the University of Rochester, Cornell University and New York University.